Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Asset Resilience Ratio
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A asset resilience ratio. Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has an Asset Resilience Ratio of 34.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Wuhan Easy Diagnosis Biomedicine Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2019–2025)
Asset resilience ratio of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2019 to 2025. This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Asset Resilience Ratio has changed over time. Read 002932 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002932 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.07 Billion | 34.47% |
| Total Liquid Assets | CN¥2.07 Billion | 34.47% |
Asset Resilience Insights
- Very High Liquidity: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A maintains exceptional liquid asset reserves at 34.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 5.11% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 15.99% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Asset Resilience Ratio by Year (2019–2025)
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.59% | CN¥394.35 Million ≈ $57.71 Million |
CN¥5.98 Billion ≈ $875.11 Million |
+5.62pp |
| 2024-12-31 | 0.97% | CN¥64.12 Million ≈ $9.38 Million |
CN¥6.59 Billion ≈ $964.77 Million |
-0.69pp |
| 2023-12-31 | 1.66% | CN¥122.59 Million ≈ $17.94 Million |
CN¥7.39 Billion ≈ $1.08 Billion |
-19.59pp |
| 2022-12-31 | 21.25% | CN¥1.95 Billion ≈ $285.75 Million |
CN¥9.19 Billion ≈ $1.34 Billion |
+0.76pp |
| 2021-12-31 | 20.49% | CN¥700.00 Million ≈ $102.43 Million |
CN¥3.42 Billion ≈ $500.03 Million |
+6.47pp |
| 2020-12-31 | 14.02% | CN¥200.00 Million ≈ $29.27 Million |
CN¥1.43 Billion ≈ $208.76 Million |
-17.31pp |
| 2019-12-31 | 31.33% | CN¥200.00 Million ≈ $29.27 Million |
CN¥638.42 Million ≈ $93.42 Million |
-- |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more